Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell

• Status: Completed
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the effect of dapagliflozin on the incretin sensitivity of the pancreatic beta cell.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: AstraZeneca
• Treatments: Dapagliflozin; Incretins

Criteria

Inclusion Criteria:

• Type 2 diabetes for dapagliflozin arm

• Normal glucose tolerance (fasting plasma glucose <100 mgd/l, HbA1c <6.0%) for normal glucose tolerance arm

• Age 18 to 75 years

• BMI <35 kg/m2

• For type 2 diabetes patients, at least 3 months of treatment period and HbA1c 7.5 to 11.0% and treatment with lifestyle modification and/or metformin or sulfonylurea

Exclusion Criteria:

• Who is allergic to dapagliflozin

• Type 1 diabetes

• Patients with history of diabetic ketoacidosis

• Reduced renal function (eGFR <60ml/min/1.73m2)

• Taking loop diuretics or dehydrated patient

• History of hypotension when taking hypertensive medication

• Diagnosed with heart failure

• Diagnosed with cerebral infarction

• Taking insulin, DPP-4 inhibitor, GLP-1 analogue, pioglitazone, alpha-glucosidase inhibitor

• Above upper limit of normal hematocrit range (male 39-52%, female 36-48%)

• Pregnant or breastfeeding women

• History of recurrent genitourinary infection

• AST/ALT more than two fold increased above normal upper limit

• Hemolytic disorder